Mental Disorder and Mental Illness

Sarvarthapedia

Sarvarthapedia (Core Areas)

Mental Disorder and Mental Illness (up to 2026) under Disease and Detection of Disease, spanning 12 volumes Each volume covers conceptual foundations, diagnostic systems, specific disorder categories, assessment tools, emerging biomarkers, digital mental health, therapeutics, and global perspectives. The outline is designed to be exhaustive for a reference work of this scope.

Volume 1: Foundations of Mental Disorder – Concepts, History, and Classification

Part I: Defining Mental Disorder

• The concept of mental illness across cultures and eras
• Operational definitions: distress, dysfunction, deviance, danger
• Mental disorder vs. neurological disease vs. behavioral condition
• The biopsychosocial model (Engel, 1977) and its modern updates

Part II: Historical Perspectives (Antiquity–1970s)

• Ancient views: demonic possession, trephination, humoral theory
• Asylums and moral treatment (Pinel, Tuke, Rush)
• Kraepelin’s dichotomy (dementia praecox vs. manic-depression)
• Freudian psychoanalysis and its diagnostic legacy
• Mid-20th century: psychosurgery, ECT, insulin coma therapy
• Deinstitutionalization movement (1960s–1980s)

Part III: Diagnostic Classification Systems

• DSM-I to DSM-5-TR (2022) – history, controversies, changes
• ICD-8 to ICD-11 (2022) – mental disorders chapter
• Comparison of DSM vs. ICD approaches
• Dimensional vs. categorical models (HiTOP, RDoC)

Part IV: Epidemiology and Public Health

• Global burden of mental disorders (GBD 2021 update)
• Prevalence, incidence, and comorbidity patterns
• Social determinants (poverty, trauma, discrimination, inequality)
• Mental health economics and cost-of-illness studies

Part V: Ethics, Stigma, and Legal Frameworks

• Informed consent in psychiatric treatment
• Involuntary commitment and civil rights
• Mental health parity laws (US MHPAEA, UK Mental Health Act)
• Anti-stigma campaigns (e.g., WHO’s “The Great Push”)
• Cultural safety and diagnostic bias

---

Volume 2: Neurobiology and Etiology of Mental Disorders

Part I: Neuroanatomy and Neural Circuits

• Prefrontal cortex, amygdala, hippocampus, anterior cingulate, insula
• Default mode, salience, and central executive networks
• Limbic system and emotional regulation
• Basal ganglia circuits in OCD and tic disorders

Part II: Neurotransmitter and Neuroendocrine Systems

• Serotonin (5-HT) – depression, anxiety, OCD
• Dopamine – schizophrenia, addiction, bipolar mania
• Norepinephrine – PTSD, panic, ADHD
• Glutamate and GABA – psychosis, anxiety, autism
• HPA axis and cortisol dysregulation in depression and PTSD
• Thyroid, sex hormones, and mental health

Part III: Genetic and Epigenetic Basis

• Heritability estimates from twin and family studies
• Genome-wide association studies (GWAS) – major findings up to 2026
• Polygenic risk scores (PRS) – clinical utility and limitations
• Rare variants (CNVs) in schizophrenia and autism
• Epigenetic mechanisms: DNA methylation, histone modification, non-coding RNAs
• Gene-environment interactions (e.g., 5-HTTLPR × stress)

Part IV: Neuroimmunology and Inflammation

• Cytokine hypotheses of depression and fatigue
• Microglial activation in psychosis and bipolar disorder
• Autoimmune encephalitis mimicking psychiatric disorders (anti-NMDA receptor, etc.)
• Gut-brain axis and microbiome in anxiety and depression

Part V: Neuroplasticity and Developmental Origins

• Early-life adversity and brain development
• Critical periods and sensitive windows
• Neurogenesis and antidepressant mechanisms
• The role of sleep and circadian rhythms

---

Volume 3: Assessment, Interviewing, and Psychological Testing

Part I: The Psychiatric Interview

• Mental status examination (MSE) – appearance, speech, mood, affect, thought content, perception, cognition, insight, judgment
• History taking (chief complaint, HPI, past psychiatric, medical, family, social)
• Suicide and violence risk assessment (C-SSRS, SAD PERSONS scale)
• Motivational interviewing techniques

Part II: Structured and Semi-Structured Interviews

• SCID (for DSM-5 and ICD-11)
• MINI International Neuropsychiatric Interview
• CIDI (Composite International Diagnostic Interview)
• ADOS-2 for autism spectrum disorder

Part III: Symptom Rating Scales and Questionnaires

• Depression: HAM-D, MADRS, PHQ-9, BDI-II, QIDS
• Anxiety: HAM-A, GAD-7, BAI, OASIS
• Mania: YMRS, Altman Self-Rating Mania Scale
• Psychosis: PANSS, BPRS, SAPS, SANS
• OCD: Y-BOCS
• PTSD: CAPS-5, PCL-5
• Eating disorders: EDE-Q, SCOFF
• ADHD: ASRS, Conners’ Rating Scales

Part IV: Personality and Projective Tests

• MMPI-3 (2020 update)
• PAI (Personality Assessment Inventory)
• Rorschach Inkblot Test (Exner system, R-PAS)
• TAT (Thematic Apperception Test)
• Millon Clinical Multiaxial Inventory (MCMI-IV)

Part V: Neuropsychological Testing

• General cognitive screening: MoCA, MMSE, RBANS
• Executive function: Trail Making Test, Stroop, Wisconsin Card Sorting
• Memory: WMS-IV, CVLT, RAVLT
• Attention: CPT-3
• Premorbid IQ: WTAR, TOPF

Part VI: Cultural and Linguistic Adaptation

• Culturally adapted assessment tools
• Idioms of distress (e.g., ataque de nervios, khyâl cap)
• Use of interpreters in psychiatric assessment

---

Volume 4: Neurodevelopmental and Childhood-Onset Disorders

Part I: Intellectual Disability (ID)

• Definition, severity levels, adaptive functioning (Vineland-3, ABAS-3)
• Genetic causes (Down, Fragile X, Rett, Williams, Angelman)
• Diagnostic tools: WAIS-IV, WISC-V, Leiter-3
• Differential diagnosis from global developmental delay

Part II: Autism Spectrum Disorder (ASD)

• Core domains: social communication deficits, restricted/repetitive behaviors
• Prevalence and gender differences (including female phenotype)
• Diagnostic instruments: ADOS-2, ADI-R, M-CHAT-R/F
• Biomarkers: eye tracking, EEG, neuroimaging (still research)
• Co-occurring conditions (ID, epilepsy, anxiety, GI issues)
• Adult autism and late diagnosis

Part III: Attention-Deficit/Hyperactivity Disorder (ADHD)

• Inattentive, hyperactive-impulsive, combined presentations
• Developmental trajectory (childhood to adulthood)
• Rating scales: Vanderbilt, ASRS, Conners’
• Neuropsychological and continuous performance tests
• Comorbidities: ODD, CD, learning disorders, anxiety, depression

Part IV: Specific Learning Disorders

• Dyslexia, dyscalculia, dysgraphia, and nonverbal learning disability
• Psychoeducational assessment (WIAT, KTEA, Woodcock-Johnson)
• Response to intervention (RTI) models

Part V: Motor Disorders and Tics

• Developmental coordination disorder (DCD)
• Stereotypic movement disorder
• Tourette’s disorder and persistent tic disorders
• Assessment: Yale Global Tic Severity Scale (YGTSS)

Part VI: Early-Onset Psychosis and Bipolar Disorder

• Very early-onset schizophrenia (before age 13)
• Pediatric bipolar disorder (controversies, differentiation from ADHD)

---

Volume 5: Schizophrenia Spectrum and Psychotic Disorders

Part I: Schizophrenia

• Diagnostic criteria (DSM-5-TR, ICD-11)
• Positive symptoms (delusions, hallucinations, disorganized speech/behavior)
• Negative symptoms (blunted affect, alogia, avolition, anhedonia, asociality)
• Cognitive impairment (working memory, executive function, attention)
• Phases: prodromal, active, residual
• Subtypes (historical: paranoid, disorganized, catatonic, undifferentiated)

Part II: Other Psychotic Disorders

• Schizoaffective disorder (bipolar and depressive types)
• Schizophreniform disorder
• Brief psychotic disorder
• Delusional disorder (erotomanic, grandiose, jealous, persecutory, somatic)
• Shared psychotic disorder (folie à deux)
• Catatonia (retarded, excited, malignant) – assessment (Bush-Francis scale)

Part III: Assessment Tools for Psychosis

• PANSS, BPRS, SAPS, SANS
• Scale for the Assessment of Negative Symptoms (SANS update)
• Clinical Global Impression – Schizophrenia (CGI-SCH)

Part IV: Neurobiology of Psychosis

• Dopamine hypothesis and its revisions
• Glutamate/NMDA hypofunction hypothesis
• Structural MRI findings (ventricular enlargement, gray matter loss)
• Connectome dysfunction and dysconnectivity hypothesis

Part V: Early Detection and Prodrome

• Ultra-high risk (UHR) criteria
• CAARMS (Comprehensive Assessment of At-Risk Mental States)
• SIPS (Structured Interview for Prodromal Syndromes)
• Biomarkers of conversion (neuroimaging, EEG, inflammatory markers)

---

Volume 6: Mood Disorders – Depression and Bipolar

Part I: Major Depressive Disorder (MDD)

• Single and recurrent episodes – severity specifiers
• Atypical, melancholic, catatonic, peripartum, seasonal (SAD) features
• Persistent depressive disorder (dysthymia)
• Premenstrual dysphoric disorder (PMDD)
• Disruptive mood dysregulation disorder (DMDD – children)

Part II: Bipolar Spectrum Disorders

• Bipolar I disorder (mania + depression)
• Bipolar II disorder (hypomania + major depression)
• Cyclothymic disorder
• Rapid cycling (≥4 episodes/year)
• Mixed features specifier

Part III: Assessment Scales for Mood Disorders

• Depression: HAM-D, MADRS, PHQ-9, QIDS-SR, BDI-II
• Mania/hypomania: YMRS, Altman Self-Rating Scale, MDQ
• Bipolarity screening: HCL-32, BSDS

Part IV: Neurobiology of Mood Disorders

• Monoamine hypotheses (serotonin, norepinephrine, dopamine)
• Neurotrophic hypothesis (BDNF)
• Circadian rhythm disruption
• Inflammatory and metabolic pathways
• Structural and functional neuroimaging findings

Part V: Suicidality and Self-Harm

• Suicide risk assessment (C-SSRS, SAD PERSONS, Columbia Protocol)
• Non-suicidal self-injury (NSSI)
• Ecological momentary assessment (EMA) for real-time risk
• Biomarkers of suicide risk (e.g., low serotonin, high cortisol)

---

Volume 7: Anxiety, Obsessive-Compulsive, Trauma, and Stressor-Related Disorders

Part I: Anxiety Disorders

• Generalized anxiety disorder (GAD) – excessive worry, somatic symptoms
• Panic disorder and agoraphobia
• Social anxiety disorder (social phobia)
• Specific phobias (animal, natural environment, blood-injection-injury, situational)
• Separation anxiety disorder (adult and child)
• Selective mutism

Part II: Assessment of Anxiety

• HAM-A, GAD-7, BAI, OASIS
• Panic Disorder Severity Scale (PDSS)
• Liebowitz Social Anxiety Scale (LSAS)

Part III: Obsessive-Compulsive and Related Disorders

• OCD (obsessions and compulsions) – insight specifiers
• Body dysmorphic disorder (BDD)
• Hoarding disorder
• Trichotillomania (hair-pulling)
• Excoriation (skin-picking) disorder
• Y-BOCS and D-YBOCS for children

Part IV: Trauma and Stressor-Related Disorders

• PTSD (DSM-5-TR criteria, including dissociative subtype)
• Complex PTSD (ICD-11)
• Acute stress disorder
• Adjustment disorders
• Prolonged grief disorder (ICD-11, DSM-5-TR update)

Part V: Assessment of PTSD

• CAPS-5 (Clinician-Administered PTSD Scale)
• PCL-5 (PTSD Checklist)
• Life Events Checklist (LEC-5)

Part VI: Neurobiology of Fear and Stress

• Amygdala, medial prefrontal cortex, hippocampus
• Fear conditioning and extinction
• HPA axis dysregulation
• Epigenetics of childhood trauma

---

Volume 8: Somatic, Dissociative, Feeding/Eating, and Elimination Disorders

Part I: Somatic Symptom and Related Disorders

• Somatic symptom disorder (with/without predominant pain)
• Illness anxiety disorder (hypochondriasis)
• Conversion disorder (functional neurological symptom disorder)
• Factitious disorder (imposed on self or another – Munchausen by proxy)
• Psychological factors affecting other medical conditions

Part II: Dissociative Disorders

• Dissociative identity disorder (multiple personality disorder)
• Dissociative amnesia (with/without dissociative fugue)
• Depersonalization/derealization disorder
• Assessment: DES (Dissociative Experiences Scale), SCID-D

Part III: Feeding and Eating Disorders

• Anorexia nervosa (restricting and binge-purge subtypes)
• Bulimia nervosa
• Binge-eating disorder
• Avoidant/restrictive food intake disorder (ARFID)
• Pica and rumination disorder
• Assessment: EDE-Q, EDE interview, SCOFF

Part IV: Elimination Disorders

• Enuresis (nocturnal, diurnal)
• Encopresis (with/without constipation)

---

Volume 9: Personality Disorders, Impulse Control, and Disruptive Behavior Disorders

Part I: Personality Disorders – General Concepts

• DSM-5-TR alternative model (AMPD) – Criterion A (impairment) and B (pathological traits)
• ICD-11 dimensional model (severity + trait domains)
• Cluster A (odd/eccentric): paranoid, schizoid, schizotypal
• Cluster B (dramatic/erratic): antisocial, borderline, histrionic, narcissistic
• Cluster C (anxious/fearful): avoidant, dependent, obsessive-compulsive personality disorder

Part II: Borderline Personality Disorder (BPD)

• Diagnostic criteria (affective instability, identity disturbance, impulsivity, suicidality/NSSI, emptiness, abandonment fears, anger, dissociation)
• Assessment: Zanarini Rating Scale, McLean Screening Instrument
• Neurobiology: frontolimbic dysfunction

Part III: Antisocial Personality Disorder and Psychopathy

• Conduct disorder (childhood antecedent)
• Psychopathy checklist (PCL-R) – Hare
• Differences between ASPD and psychopathy

Part IV: Impulse-Control and Conduct Disorders

• Oppositional defiant disorder (ODD)
• Intermittent explosive disorder (IED)
• Pyromania and kleptomania

Part V: Paraphilic Disorders

• Voyeuristic, exhibitionistic, frotteuristic, sexual masochism, sexual sadism, pedophilic, fetishistic, transvestic disorder
• Distinction between paraphilia and paraphilic disorder

---

Volume 10: Neurocognitive, Sleep-Wake, and Sexual Dysfunctions

Part I: Neurocognitive Disorders (NCDs)

• Delirium – hyperactive, hypoactive, mixed
• Major and mild NCD due to:
• Alzheimer’s disease (early vs. late onset)
• Frontotemporal lobar degeneration (behavioral variant, PPA)
• Lewy body disease (dementia with Lewy bodies, Parkinson’s disease dementia)
• Vascular disease (post-stroke, subcortical ischemic)
• Traumatic brain injury (chronic traumatic encephalopathy)
• HIV infection, prion disease, Huntington’s, Parkinson’s
• Assessment: MoCA, MMSE, RBANS, CDR, neuropsychological battery
• Biomarkers: CSF Aβ42/p-tau, amyloid/tau PET, MRI volumetrics

Part II: Sleep-Wake Disorders

• Insomnia disorder (acute, chronic)
• Hypersomnolence disorder (including idiopathic hypersomnia)
• Narcolepsy type 1 and 2 (low orexin/hypocretin)
• Breathing-related sleep disorders (obstructive sleep apnea)
• Circadian rhythm disorders (delayed/advanced phase, shift work, jet lag)
• Parasomnias (REM sleep behavior disorder, nightmare disorder, sleepwalking)
• Assessment: polysomnography, actigraphy, MSLT, sleep diaries

Part III: Sexual Dysfunctions

• Delayed ejaculation, erectile disorder, female orgasmic disorder, female sexual interest/arousal disorder, genito-pelvic pain/penetration disorder, male hypoactive sexual desire disorder, premature ejaculation
• Assessment: clinical interview, validated scales (FSFI, IIEF)

Part IV: Gender Dysphoria

• Diagnostic criteria (children, adolescents, adults)
• Assessment: gender identity interviews, Utrecht Gender Dysphoria Scale
• Distinction from transvestic disorder

---

Volume 11: Emerging Technologies, Biomarkers, and Digital Mental Health (2020–2026)

Part I: Digital Phenotyping and Passive Sensing

• Smartphone-based behavioral data (GPS, accelerometry, keyboard dynamics, voice, sleep)
• Wearables (heart rate, HRV, skin conductance, actigraphy)
• Prediction of relapse (mania, depression, psychosis)
• Ecological momentary assessment (EMA) for mood and symptoms

Part II: Machine Learning and AI in Psychiatry

• Predictive models for treatment response (antidepressants, antipsychotics, psychotherapy)
• Natural language processing (NLP) for suicide risk from clinical notes or social media
• Speech and facial expression analysis for depression and schizophrenia
• Neuroimaging-based diagnostic classifiers (support vector machines, deep learning)
• Ethical challenges (algorithmic bias, black-box interpretability)

Part III: Biomarkers and Laboratory Tests

• Blood biomarkers: CRP, IL-6, BDNF, kynurenine pathway metabolites
• Genetic risk scores (polygenic risk scores) – current limitations
• EEG and event-related potentials (mismatch negativity, P300, resting-state alpha)
• Eye tracking (smooth pursuit, saccades) for psychosis risk
• Salivary cortisol, alpha-amylase, and oxytocin
• Inflammatory and autoimmune markers (anti-NMDA receptor, anti-TPO)

Part IV: Neuroimaging Biomarkers

• Structural MRI (cortical thickness, subcortical volumes)
• Diffusion tensor imaging (DTI) for white matter integrity
• Resting-state fMRI (functional connectivity networks)
• PET tracers (amyloid, tau, microglial activation, dopamine D2)
• Magnetic resonance spectroscopy (GABA, glutamate, glutathione)

Part V: Digital Therapeutics and App-Based Interventions

• FDA-approved digital therapeutics (e.g., reSET for substance use, EndeavorRx for ADHD)
• CBT-based apps (e.g., Woebot, SilverCloud, MindSpot)
• Ecological momentary intervention (EMI)
• Chatbots and large language models (GPT-4, etc.) for psychoeducation and support

Part VI: Telepsychiatry and Remote Assessment

• Videoconferencing-based MSE and cognitive testing
• Remote pharmacogenetic testing
• Regulatory changes post-COVID-19 (DEA rules, interstate compacts)

---

Volume 12: Treatment, Prevention, and Global Mental Health

Part I: Pharmacotherapy

• Antidepressants (SSRIs, SNRIs, TCAs, MAOIs, atypical) – mechanisms, side effects, monitoring
• Antipsychotics (first-generation/haloperidol; second-generation/clozapine, risperidone, aripiprazole, cariprazine) – metabolic monitoring
• Mood stabilizers (lithium, valproate, lamotrigine, carbamazepine)
• Anxiolytics/hypnotics (benzodiazepines, buspirone, z-drugs, melatonin agonists)
• Stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine) for ADHD
• Pharmacogenetics (CYP450 testing, HLA-B*1502 for carbamazepine)

Part II: Psychotherapy and Psychosocial Interventions

• Cognitive-behavioral therapy (CBT) – protocols for depression, anxiety, OCD, PTSD
• Dialectical behavior therapy (DBT) for BPD
• Interpersonal therapy (IPT)
• Psychodynamic therapy (brief, long-term)
• Acceptance and commitment therapy (ACT)
• Mindfulness-based cognitive therapy (MBCT)
• Family therapy and couples therapy
• Group therapy (support groups, skills groups)

Part III: Brain Stimulation Therapies

• Electroconvulsive therapy (ECT) – indications (severe depression, catatonia, mania), technique, cognitive side effects
• Repetitive transcranial magnetic stimulation (rTMS) – standard, theta-burst (iTBS, cTBS)
• Deep TMS (dTMS)
• Vagus nerve stimulation (VNS)
• Deep brain stimulation (DBS) for treatment-resistant depression and OCD
• Magnetic seizure therapy (MST) – emerging

Part IV: Lifestyle, Complementary, and Integrative Approaches

• Exercise and physical activity interventions
• Sleep hygiene and chronotherapy (bright light therapy, dark therapy, sleep deprivation)
• Nutrition and nutraceuticals (omega-3s, folate, S-adenosylmethionine, vitamin D, N-acetylcysteine)
• Yoga, meditation, and mindfulness
• Ketamine and esketamine (intranasal) for treatment-resistant depression
• Psilocybin, MDMA, and psychedelic-assisted therapy – clinical trial data up to 2026

Part V: Prevention and Early Intervention

• Universal, selective, and indicated prevention
• School-based mental health screening
• Youth early psychosis programs (e.g., RAISE, EASA)
• Suicide prevention gatekeeper training (QPR, ASIST)

Part VI: Global Mental Health

• Mental health Gap Action Programme (mhGAP) – WHO
• Task-sharing with community health workers (e.g., Friendship Bench – Zimbabwe)
• Scalable psychosocial interventions (Problem Management Plus, Thinking Healthy)
• Refugee and displaced populations mental health
• Humanitarian emergencies and trauma-informed care

Part VII: Mental Health Policy and Systems

• Integration into primary care (collaborative care model)
• Mental health insurance parity and reimbursement
• Peer support specialists
• Forensic psychiatry and mental health courts

---

Appendixes (across all volumes)

1. Glossary of psychiatric terms (500+ entries)
2. DSM-5-TR and ICD-11 crosswalk (diagnostic codes and criteria summaries)
3. Rating scales reference table (acronyms, number of items, administration time, scoring)
4. Psychotropic medication tables (class, mechanism, dosing, side effects, monitoring, pregnancy category)
5. Brain stimulation safety and contraindications (ECT, rTMS, DBS)
6. Genetic testing guide for psychiatric disorders (when to order, interpretation)
7. Emergency psychiatry algorithms (agitation, suicide risk, catatonia, serotonin syndrome, neuroleptic malignant syndrome)
8. Cultural formulation interview (CFI) – DSM-5
9. Mental health resources by country (helplines, advocacy groups, professional societies)
10. Timeline of major discoveries in psychiatry (1840–2026)
11. Legal standards for involuntary commitment (US, UK, EU, Australia)
12. Index (cross-referenced by disorder, symptom, assessment tool, treatment, and volume)

---